Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer.
- Author:
Shu-Fen LI
1
;
Xu WANG
;
Chen WANG
;
Li-Hong HE
;
Ye-Hui SHI
;
Chun-Fang HAO
;
Guo-Lei DONG
;
Zhong-Sheng TONG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Anthracyclines; pharmacology; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Breast Neoplasms; drug therapy; pathology; Capecitabine; Deoxycytidine; administration & dosage; adverse effects; analogs & derivatives; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; administration & dosage; adverse effects; analogs & derivatives; Humans; Lung Neoplasms; drug therapy; secondary; Lymphatic Metastasis; Middle Aged; Remission Induction; Survival Rate; Taxoids; administration & dosage; adverse effects
- From: Chinese Journal of Oncology 2008;30(12):944-946
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of docetaxel and capecitabine combination chemotherapy (DC regimen) for patients with anthracycline-resistant metastatic breast cancer.
METHODSThirty-two patients with anthracycline-resistant metastatic breast cancer were treated with a docetaxel and capecitabine combination regimen. All patients received oral administration of capecitabine at a dose of 1250 mg/m(2) twice daily, within 30 min after meal on D1 to D14, and intravenous infusion of docetaxel at a dose of 75 mg/m(2) on D1. The regimen was repeated every 3 weeks.
RESULTSA total of 126 cycles of DC regimen were administered in the 32 cases, with a median of 4 cycles. The overall response rate was 46.9%. Among the 32 patients, there were complete response in 1, partial response in 14, stable disease in 11 and progressive disease in 6 cases. The median time to progression (TTP) was 5.6 months. The one-year survival rate was 56.3%. The effective cases in different metastatic organs were: 8 cases in the lung, 6 cases in the liver, 3 cases in the soft tissue and 3 cases in the lymph nodes. The common adverse reactions were myelosuppression, hand-foot syndrome, nausea and vomiting. Neutropenia was observed in 84.4% of the patients. Two patients developed degree IV myelosuppression.
CONCLUSIONThe combination chemotherapy regimen of docetaxel plus capecitabine is well-tolerated and effective for anthracycline-resistant metastatic breast cancer.